GSK

GSK Plc Form 6-K Summary

Business Context and Reporting Period

This Form 6-K filing by GSK Plc, dated October 17, 2023, serves as a transaction notification for the month of October 2023. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. These transactions were executed on October 13, 2023, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).

Key Financial Metrics

The filing does not contain company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific insider transactions involving the re-investment of dividends paid on October 12, 2023.

Material Changes

No material changes to the company's financial position or operations are reported in this filing. The document details routine compliance disclosures regarding the increase in shareholdings of specific directors and officers due to dividend re-investment plans.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, future guidance, outlook, risk factors, or contingencies. It is a statutory notification of specific share transactions.

Key Facts for Investor Verification

• Transaction Nature: All reported acquisitions were automatic re-investments of dividends paid on October 12, 2023, not open-market purchases.
• Participants: Transactions involved the Chief Strategy Officer, Company Secretary, and six Independent Non-Executive Directors.
• Share Classes: Transactions occurred in both Ordinary Shares (held in ISAs) and American Depositary Shares (ADSs).
• Volume: The total volume of shares acquired by the listed individuals was minimal (32 Ordinary Shares and 85 ADSs).